# Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer

> **NCT00589186** · PHASE2 · UNKNOWN · sponsor: **National Cancer Centre, Singapore** · enrollment: 35 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** Ad5F35-LMP1/LMP2-transduced autologous dendritic cells
- **DRUG:** celecoxib
- **OTHER:** flow cytometry
- **OTHER:** immunoenzyme technique
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00589186
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-11
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2013-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00589186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00589186, "Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00589186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*